HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Press Release All Versions of this Article: CJN.02730608v1 4/4/755    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parfrey, P. S. Articles by Lefebvre, P. Search for Related Content PubMed PubMed Citation Articles by Parfrey, P. S. Articles by Lefebvre, P.

Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD Patients: A Meta-Analysis

Patrick S. Parfrey^*, Maria Lauve, Dominick Latremouille-Viau, and Patrick Lefebvre

^* Division of Nephrology, Health Sciences Center, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; Analysis Group, Inc., Dallas, Texas; Groupe D'Analyse, Ltée, Montréal, Québec, Canada

Correspondence: Dr. Patrick S. Parfrey, Health Science Centre, 300 Prince Phillip Drive, Street John's, NL A1B 3V6 Canada. Phone: 709-777-7261; Fax: 709777-6995; E-mail: pparfrey{at}mun.ca

Background and objectives: The purpose was to evaluate changes in the left ventricular mass index (LVMi) among anemic chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients treated with recombinant human erythropoietin (EPO).

Design, setting, participants, & measurements: A systematic review of the literature, reporting LVMi for patients before and after EPO therapy, was performed. The change in LVMi from baseline to the end of treatment was calculated and stratified by severity of anemia at baseline, target hemoglobin (Hb), and stage of kidney disease.

Results: Fifteen eligible studies involving 1731 patients were identified. Cohorts with severe anemia at baseline (<10 g/dl), when given EPO using a lower target level (Hb 12 g/dl or Hct 36%) experienced significant reductions in LVMi (–32.7 g/m²; 95% CI: –49.4 to –16.1, P < 0.05). However, these studies lacked control groups. Cohorts with moderate anemia at baseline showed insignificant changes in LVMi: 5.3 g/m² (95% CI: –0.8 to 11.3) for patients assigned to a lower target, and –6.6 g/m² (95% CI: –17.2 to 4.0) for patients assigned to a higher target (Hb > 12 g/dl or Hct > 36%). The effect size was similar in direction for both CKD and ESRD cohorts.

Conclusions: Aggregated results from multiple studies suggest that in severe anemia conventional Hb targets for EPO therapy are associated with a reduction in LVMi, but that in moderate anemia target Hb above 12 g/dl does not have a significant beneficial impact on LVMi compared with conventional targets.

This article has been cited by other articles:

				G. Bayliss and J. Danziger Nocturnal versus conventional haemodialysis: some current issues Nephrol. Dial. Transplant., September 19, 2009; (2009) gfp491v1. [Full Text] [PDF]